Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 13/20 | 0.54 |
| ▸ | PLK1 | P53350 | 6/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.45 |
| ▸ | CDK2 | P24941 | 4/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.45 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 5/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND3 | P30281 | 1/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15377850 | 0.95 | TTK (0.60) | TTKPLK1CCNA2CDK2CCNA1 | |
| SCHEMBL526272 | 0.92 | TTK (0.57) | TTKPLK1CCNA2CDK2CCNA1 | |
| SCHEMBL526270 | 0.89 | IGF1R (0.52) | TTKPLK1CCNA2CDK2CCNA1 | |
| SCHEMBL525856 | 0.89 | TTK (0.57) | TTKPLK1CCNA2CDK2CCNA1 | |
| SCHEMBL526113 | 0.89 | TTK (0.53) | TTKPLK1CCNA2CDK2CCNA1 | |
| SCHEMBL523963 | 0.86 | TTK (0.48) | TTKPLK1CCNA2CDK2CCNA1 | |
| SCHEMBL525576 | 0.86 | TTK (0.55) | TTKPLK1CCNA2CDK2CCNA1 | |
| SCHEMBL526080 | 0.86 | TTK (0.69) | TTKPLK1CCNA2CDK2CCNA1 | |
| SCHEMBL525746 | 0.84 | TTK (0.71) | TTKPLK1CCNA2CDK2CCNA1 | |
| SCHEMBL12698308 | 0.84 | TTK (0.59) | TTKPLK1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9333205-B2 | Isoxazolo-quinazolines as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-10 | — | — | US | disclosed |
| US-9333205-B2 | Isoxazolo-quinazolines as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-10 | — | — | US | disclosed |
| US-9333205-B2 | Isoxazolo-quinazolines as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-10 | — | — | US | disclosed |
| EP-2598508-B1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-04-22 | — | — | EP | disclosed |
| EP-2598508-B1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-04-22 | — | — | EP | disclosed |
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-06 | — | — | US | disclosed |
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-06 | — | — | US | disclosed |
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-06 | — | — | US | disclosed |
| EP-2598508-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | Nerviano Medical Sciences S.r.l. (IT) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013557-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012013557-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | CSNK1A1, RPS6KA1, CSNK2A1 | TTK 341/4885PLK1 183/4885CCNA2 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.